Turning fast food
into slow food.
A 45-minute confidential briefing on SIGRID and the SiPore® platform — a clinically validated, non-systemic OTC solution that reduces the metabolic impact of modern meals. 15 years of R&D. SHINE pivotal trial (n=318) independently published in eClinicalMedicine (The Lancet Discovery Science).
14
Days
06
Hrs
07
Min
53
Sec
15 yrs
R&D & clinical
n=318
SHINE pivotal
6
Clinical trials
Q1 2027
EU CE Mark exp.
Reserve your seat
Confidential briefing
Agenda · 45 minutes
From science
to partnerships.
Peer-reviewed
SHINE pivotal trial · eClinicalMedicine, The Lancet Discovery Science
Chapter I
The SiPore® platform
Why slowing carb & fat breakdown matters in the age of GLP-1s — and the science behind it.
Chapter II
Clinical validation
SHINE pivotal trial (n=318), peer-reviewed in eClinicalMedicine. Mode of action, efficacy, safety.
Chapter III
Commercial traction
DTC, HCP and e-pharmacy footprint. Subscription retention. First licensing agreement signed in oral health.
Chapter IV
Live Q&A
Direct questions to the CEO. Moderated by Peter Moeller.
A single sachet,
taken with the meal.
SiPore® is a mesoporous silica — non-systemic, gut-acting, with a decade-plus safety profile. Designed for daily use alongside the meals that drive glycaemic spikes.
Non-systemic
Acts in the gut. Not absorbed into the bloodstream.
Daily-use safety
Established tolerability across six clinical trials.
Modern lifestyle fit
Discreet sachet · with the meal · no prescription.
A private briefing,
not a roadshow.
The session is moderated by Peter Moeller with SIGRID leadership presenting the science, the commercial state of play, and the partnership pipeline. Attendance is limited to forty confidential seats. Questions are taken live.
You will leave with a clear view of the asset, the clinical evidence base, the route to market, and the terms under which Moeller & Co. is convening capital around it.
Validation is complete. Monetization has begun.
Independently validated
SHINE pivotal trial published in eClinicalMedicine (The Lancet Discovery Science). 6 trials, 9 peer-reviewed publications.
Market access secured
Launched as a Medical Food in the United States. Clear pathway to EU MDR Class IIb medical device — CE Mark expected Q1 2027.
First license signed
Exclusive global licensing agreement with a leading European oral health player. Active partner dialogues across metabolic health.